| 血小板生成素受体激动剂的临床应用及研究进展 |
| |
| 引用本文： | 李洋.血小板生成素受体激动剂的临床应用及研究进展[J].国际输血及血液学杂志,2014,37(6):584-588. |
| |
| 作者姓名： | 李洋 |
| |
| 作者单位： | 中国医学科学院北京协和医学院血液学研究所血液病医院, 天津,300020 |
| |
| 基金项目： | 国家自然科学基金资助项目(81270581)Project No.81270581 |
| |
| 摘 要： | 血小板减少症为临床常见的疾病,可见于血液系统疾病与非血液系统疾病.随着对促血小板生成药物研究的深入,血小板生成素受体激动剂（TPORA）罗米司亭及艾曲泊帕的临床应用,可有效提高患者血小板计数,为治疗血小板减少症提供新的治疗方法.笔者拟就TPORA的作用机制、其在血液系统疾病及肝病相关的血小板减少症中的临床应用的进展进行综述.
|
| 关 键 词： | 血小板生成素受体激动剂 罗米司亭 艾曲泊帕 血小板减少症 药物疗法 |
Clinical Applications and Advances of Thrombopoietin Receptor Agonist |
| |
| Li Yang.Clinical Applications and Advances of Thrombopoietin Receptor Agonist[J].International Journal of Blood Tranfusion and Hematology,2014,37(6):584-588. |
| |
| Authors: | Li Yang |
| |
| Institution: | Li Yang,Yang Renci(Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300020, China) |
| |
| Abstract: | Thrombocytopenia is a common clinical disorder,which could be found in hematological and non-hematological diseases.With significant advances in thrombopoietic agents,the application of thrombopoietin receptor agonist （TPORA）,romiplostim and eltrombopag,could effectively increase the platelet count of patients,and provide a new treatment for thrombocytopenia.This article review the literatures on the mechanisms and clinical use of TPORA in hematological disorders and thrombocytopenia related to hepatopathy. |
| |
| Keywords: | Thrombopoietin receptor agonists Romiplostim Eltrombopag Thrombocytopenia Drug therapy |
| 本文献已被 维普 万方数据 等数据库收录！ |
